Skip to content

Protagenic Therapeutics, Inc.\new

PTIX · OTCM

CIK 1022899fmd_1D904NPW35EMFX11CAE4VSM5MRManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2010 to Sep 30, 2026, 58 periods

Latest annual · FY2026

Millions
Total revenues
0
Operating income
(5)
Net income
1
Free cash flow
(3)

Latest quarter · Q2 FY2027

Millions
Operating income
(1)
Net income
(1)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2024 to FY2026
n/m
Revenue, 5 yearsFY2022 to FY2026
n/m
Net income, 5 yearsFY2022 to FY2026
n/m

Protagenic Therapeutics, Inc.\new (PTIX) financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2026FY2025ChangeSource
Revenue$0$010-K 2026-08-14 · proof
Operating income-$4.5 million-$2.6 million10-K 2026-08-14 · proof
Net income$1.4 million-$3.6 million10-K 2026-08-14 · proof
Cash from operating activities-$2.8 million-$1.8 million10-K 2026-08-14 · proof
Free cash flow-$2.8 million10-K 2026-08-14 · proof
Total assets$3.7 million$89,093+3,997.3%10-K 2026-08-14 · proof
Total liabilities$1 million$5 million-79.5%10-K 2026-08-14 · proof
Cash and cash equivalents$1.5 million$14,531+10,285.9%10-K 2026-08-14 · proof
What was Protagenic Therapeutics, Inc.\new (PTIX)'s revenue in fiscal 2026?
Protagenic Therapeutics, Inc.\new (PTIX) reported revenue of $0 for fiscal 2026 (the year ended Mar 31, 2026), against $0 the year before. Source: the 10-K filed with the SEC on Aug 14, 2026. SEC
What was Protagenic Therapeutics, Inc.\new (PTIX)'s operating income in fiscal 2026?
Protagenic Therapeutics, Inc.\new (PTIX) reported operating income of -$4.5 million for fiscal 2026 (the year ended Mar 31, 2026), against -$2.6 million the year before. Source: the 10-K filed with the SEC on Aug 14, 2026. SEC
What was Protagenic Therapeutics, Inc.\new (PTIX)'s net income in fiscal 2026?
Protagenic Therapeutics, Inc.\new (PTIX) reported net income of $1.4 million for fiscal 2026 (the year ended Mar 31, 2026), against -$3.6 million the year before. Source: the 10-K filed with the SEC on Aug 14, 2026. SEC
What was Protagenic Therapeutics, Inc.\new (PTIX)'s cash from operating activities in fiscal 2026?
Protagenic Therapeutics, Inc.\new (PTIX) reported cash from operating activities of -$2.8 million for fiscal 2026 (the year ended Mar 31, 2026), against -$1.8 million the year before. Source: the 10-K filed with the SEC on Aug 14, 2026. SEC
What was Protagenic Therapeutics, Inc.\new (PTIX)'s free cash flow in fiscal 2026?
Protagenic Therapeutics, Inc.\new (PTIX) reported free cash flow of -$2.8 million for fiscal 2026 (the year ended Mar 31, 2026). Source: the 10-K filed with the SEC on Aug 14, 2026. SEC
What are Protagenic Therapeutics, Inc.\new (PTIX)'s total assets?
As of Mar 31, 2026, Protagenic Therapeutics, Inc.\new (PTIX) reported total assets of $3.7 million, against $89,093 a year earlier (+3,997.3%). Source: the 10-K filed with the SEC on Aug 14, 2026. SEC
What are Protagenic Therapeutics, Inc.\new (PTIX)'s total liabilities?
As of Mar 31, 2026, Protagenic Therapeutics, Inc.\new (PTIX) reported total liabilities of $1 million, against $5 million a year earlier (-79.5%). Source: the 10-K filed with the SEC on Aug 14, 2026. SEC
What are Protagenic Therapeutics, Inc.\new (PTIX)'s cash and cash equivalents?
As of Mar 31, 2026, Protagenic Therapeutics, Inc.\new (PTIX) reported cash and cash equivalents of $1.5 million, against $14,531 a year earlier (+10,285.9%). Source: the 10-K filed with the SEC on Aug 14, 2026. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:PTIX&period_type=annual&limit=5"

Information only, not investment advice.